| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5587432 | Diabetes Research and Clinical Practice | 2017 | 31 Pages |
Abstract
Vildagliptin as an add-on to insulin treatment for 24Â months was well tolerated and led to sustained reductions in HbA1c, the dose and number of insulin injections, and the risk of hypoglycemia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu Notsu, Sayuri Tanaka, Nobuaki Kiyohara, Sayo Koike, Yuko Yamane, Yuko Tada, Motofumi Sasaki, Mika Yamauchi, Toshitsugu Sugimoto,